Smotect

Gurseet Singh is Season 3's most personally grief-driven health founder. He lost a close friend to lung cancer caused by smoking, an experience that shattered him and catalysed a lifelong mission: ensuring no one else loses a loved one to a preventable addiction. Gurseet quit smoking himself and then spent nearly a decade developing a scientifically validated solution to help millions of others quit. R&D began in 2014 with Ayurvedic formulation research, identifying 12 therapeutic herbs that could address both the physical nicotine dependency and the psychological habit patterns of smoking. In 2016, formal clinical trials commenced with 100 patients using the gold standard methodology: double-blinded, randomised, placebo-controlled, multicentric studies. The 95% success rate from these trials gave Smotect the most rigorous clinical validation of any Ayurvedic smoking cessation product in India.

Smotect is the world's first 100% natural, nicotine-free smoking cessation tablet, offering a dual-action approach: helping smokers quit the habit AND repairing the physiological damage caused by years of smoking. Unlike conventional nicotine replacement therapies (NRT) that substitute one form of nicotine addiction with another (nicotine patches, nicotine gum), Smotect eliminates nicotine dependency entirely through Ayurvedic herbal formulation. The 12 therapeutic herbs work through multiple mechanisms: reducing nicotine cravings, managing withdrawal symptoms (anxiety, irritability, insomnia), improving lung function, supporting liver detoxification, and restoring overall wellness. The tablet format is the most consumer-friendly delivery mechanism (no patches to apply, no gum to chew, no vaping devices to carry).

Amount Asked: ₹1 crore Equity Offered: 1% Implied Pre-Money Valuation: ₹100 crore

Gurseet walked into Season 3 Episode 40 with the most personally emotional health founding story of the episode. He opened with his friend's death from lung cancer, his own smoking cessation journey, and the 10-year R&D process that produced the world's first clinically validated nicotine-free smoking cessation tablet. The clinical trial data was the pitch's strongest commercial asset: 95% success rate in double-blinded randomised placebo-controlled multicentric studies is the gold standard of pharmaceutical evidence. No other Ayurvedic smoking cessation product in India has this level of clinical validation. The financial metrics were genuinely impressive: ₹4.25 crore revenue by September 2023 with 80% gross margin, 28% EBITDA, and 3,500 to 4,000 new customers per month. However, the ₹100 crore valuation at 1% equity was the most aggressive ask of Episode 40.

Aman Gupta was the first to exit, citing the founder having two businesses simultaneously. Namita Thapar exited for the same reason as Aman: the dual-business concern. Deepinder Goyal (guest Shark) exited because he did not get conviction that the product actually worked. Vineeta Singh agreed with Deepinder's efficacy concerns and could not see sufficient proof that the product reliably helped smokers quit. Anupam Mittal was the sole Shark who saw investable potential. Despite sharing some concerns about the efficacy claims, he offered a deal conditional on those claims being verified through due diligence.

Gurseet asked ₹1 crore for 1% equity (₹100 crore valuation). Four Sharks exited. Anupam offered ₹50 lakhs for 5% equity plus ₹50 lakhs debt at 15% interest for 3 years (₹10 crore valuation), conditional on efficacy claims being verified. The founder countered at ₹50 lakhs for 2% equity. Anupam refused and stated his offer was non-negotiable. The founder accepted the original 5% terms. The valuation dropped 90% from ₹100 crore ask to ₹10 crore deal, the largest single-deal valuation markdown in Episode 40.

Gurseet Singh accepted Anupam Mittal's non-negotiable offer of ₹50 lakhs for 5% equity plus ₹50 lakhs debt at 15% interest for 3 years, valuing Smotect at ₹10 crore, conditional on efficacy claims being verified. The deal brought Anupam's digital platform scaling expertise and consumer health product marketing capability to a clinically validated smoking cessation product. The 15% debt interest rate was Season 3's highest debt cost, reflecting the risk premium Anupam placed on an efficacy-conditional investment.

Our research on Smotect revealed that while they did get a deal on Shark Tank India, whether that deal closed after the show is still unclear. Early signs, however, suggest that the deal has not gone through, but this could very well be because they are still in the due diligence phase. Smotect continues operating from Mumbai with its website (smotect.com) prominently featuring "As Seen on Shark Tank India" branding. The product range has expanded to include Smotect Azaadi for gutkha and chewing tobacco cessation (available in granules, chewables, and tablets), broadening the addressable market beyond smokers to all tobacco users.